BioLargo, Inc.OTCQX: BLGO

Corporate Presentation September 2014Fall 2014

Forward Looking StatementsThe statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K for the year ended December 31, 2013.

OTCQB: BLGO

2

About BioLargowe make life better

BioLargo, Inc.• platform technology company• leveraging iodine chemistry • solving the world’s most

challenging issues in• water decontamination• disinfection• wound care• odor elimination• moisture control

Consumer products

Water disinfection

Water decontamination

Wound care & disinfection

3

BioLargo AOS Water Filter“Unprecedented Results”

• 100x more effective• 1/20th the cost• >10x faster

• Independently Tested and Verified by Acclaimed Researchers at Univ. of Alberta

4

The Science

–Not Your Grandmother’s Iodine

–Extremely high OXIDATION

–Forget what you knew before

5

Salmonella Case Study –100,000 cells = infection–94 million cases /yr –155,000 Deaths–USDA Reports cost at ≈ $2.65B/yr

6

Extreme Oxidation Potential

• Chlorine Dioxide:• 100,000 cells• 60 min. for total kill

• BioLargo AOS Filter:•10,000,000 cells•2 min. for total kill

VS.

*UP TO 100,000 Salmonella cells can be found in one mouse dropping

Commercial Pilot

Iodine + Electrolysis + Filter Media7

8

(+) (-)

H20

H20

I2

Iodine + Electrolysis + Filter Media

AOS Filter: Value Proposition

Achieves unprecedented levels of disinfection and rapidly dismantles & removes soluble organic contaminants, including toxic contaminants missed by other filterso “Hot” advanced oxidation potentialo Self regenerating coated filtration

media with no caustic chemicalso Continuous flow with no backwash

downtimeo Extremely low powero High speed, high capacity with

modular design

AOS Filter- Converts a Filter into a Reactor

(+) (-)

H20

H20

I2AOS

9

10

Delivering ProvenCompetitive Advantage

Characteristics BioLargo Competing Ozone Technology

Time o Instantaneous reduction o 5 to 6 hours

Process o Continual free-flowing o Batch processing

Energy o Very low power consumption o Significant power required

Footprint o Small o Large space needed

Results = Fraction of the cost = Not commercially cost effective

AOS rapidly dismantles difficult soluble contaminants and disinfects

< 1/20th the cost of the nearest competition

11

Impact on Every Segment of the $360B Water Industry

Athabasca Oil Sands

Food Processing Production

Process & Produced Water

Fracking Remediation Ultra-pure Cooling

Municipal Waste Water Ballast Home Applications Third World

12

Water: AOS Filter

• Where to Focus: – fastest to market– where we experience pull

• Broad effectiveness against long list of contaminant

• Global licensing model

13

Well-Positioned in CanadaCharter Member of stake holder cooperative established to resolve tailings pond water

NSERC Research Chair at the University of Alberta (Dept. of Engineering)

o BioLargo is charter member (2011)

o Joined by top Canadian oil

companies, Canadian agencies and

leading researchers from the field

o Backed in large part by the

Canadian federal government

NSERC = Natural Sciences & Engineering Research Council of Canadawww.nserc-crsng.gc.ca

o Syncrude Canada, Ltd.o Suncor Energy, Inc.o Shell Canada, Ltd.o Canadian Natural Resources, Ltd.o Total E&P Canada Ltd.o EPCOR Water Services, Inc.o BioLargo, Inc.o Alberta Innovateso Alberta Environment

14

Secured IP RightsSetting the foundation for sales & licensing with the pilot terms:

BioLargo

Owns 100%

resulting IP

95%of

revenue

$1.6M CND

to fundover 4 years

Univ. of Alberta

5%Royalty

>$3.5M CND

Grant Aid

15

Assets built to license: Advanced Wound Care

• Pathway to Success is clear for $1B+ opportunity– 510k + $500k + licensing – $5MM + per year in licensing revenues out of the gate– ≈95% of the Work is Complete– currently negotiating with three global companies

• Exceptional- Proven Leadership Team• Liquids, Hydrogels & Dressings• High Profit Margins

16

Assets built to license: Consumer Products

• Over 30 Fully Developed Products – Demo Sells Products Instantly– Multiple Product of the Year Awards– Best-In-Class (Validated @ Veritas)

• Target Licensing Revenues – $250K to $1MM Annually PER Product

• Strategic Licensing Deals in works Now- Including; #1 Brand in the USA to launch into largest retailers in industry

17

Leadership TeamExecutive

Joined BLGO

Experience

Dennis CalvertChairman, President & CEO

2003 o 20 years as an entrepreneur, investor and consultant

Kenneth CodeInventor & CTO Founder o Chemist, Entrepreneur and Creator of BioLargo’s technology

o Developing the technology since 1997

Richard Smith, PhDPresident, BioLargo Water 2014 o PhD in Viral Immunopathology &

o 10+ years working with biotech companies in Alberta, including ChemBioMed and VirRexx

Vikram Rao, PhDSr. Advisor 2010 o 30 years in petroleum industry, former CTO & EVP at Halliburton; ED of Research Triangle

Energy Consortium, author of 40+ publications and holder of 24+ patents

Harry DeLongeSr. Advisor 2011 o 40+ years as Pepsi-Cola’s Int’l V.P. of Technical Services & V.P. of Manufacturing Technology

o Water Expert

Joseph ProvenzanoV.P. of Operations 2003 o 15 years in mergers and acquisitions, operations and marketing

Robert SzolomayerDir. of Corp. Development 2004 o 35 years in Real Estate; five years managing $1B Northrop Grumman project

Steve HarrisonDir. of Int’l Ventures 2003 o 25 years of experience as an Entrepreneur and Business Founder beyond U.S. soil

Tim R. JohnsonDir. of Medical Products 2012 o 25 years medical device industry, successful entrepreneur founded, developed and sold

medical products company to Smith and Nephew

Tanya Rhodes PhDCTO Clyra Medical 2013

o Chemistry PhDo 25 years advanced wound care industry, Sr. VP, Regulatory & Innovation Smith and

Nephew

AJ Sexton VDir. of Bus. Development 2014 o 25 years Investment Banking, License FINRA Series 7, 63 and 79 licenses

18

The Plan

Unlock the value to accelerate success

Broaden shareholder base Execute the near term commercial

opportunities Partner with leaders Monetize the assets Up list & build a market

19

Company Contacts:Dennis Calvert - President & CEO 949.643.9540

AJ Sexton - Director of Bus Dev. - 949.945.8450

info@biolargo.com or aj@biolargo.com

www.biolargo.com